Human OGA/MEA5/MGEA5 ORF/cDNA clone-Adenovirus plasmid (NM_012215.3)

Cat. No.: pGMAD000486
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days

Pre-made Human OGA/MEA5/MGEA5 adenoviral expression plasmid for OGA adenovirus packaging, OGA adenovirus.

Our GM-Adenovirus vector is optimized with the GMVC-modified Adeasy adenovirus packaging system. Find more about the GMVC-modified adenovirus packaging system.

pdf Datasheet
pdf MSDS
pdf Terms of Use
Target products collection

Go to OGA/MEA5 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Purchase
Shipping fee: Limited-time free
For payment issues, contact us.


Product Description

Catalog ID pGMAD000486
Gene Name OGA
Accession Number NM_012215.3
Gene ID 10724
Species Human
Product Type Adenovirus plasmid (overexpression)
Insert Length 2751 bp
Gene Alias MEA5,MGEA5,NCOAT
Fluorescent Reporter GFP
Mammalian Cell Selection Null
Fusion Tag 6xHis (C-Terminal)
Promoter EF1
Resistance Amplicin
ORF Nucleotide Sequence ATGGTGCAGAAGGAGAGTCAAGCGACGTTGGAGGAGCGGGAGAGCGAGCTCAGCTCCAACCCTGCCGCCTCTGCGGGGGCATCGCTGGAGCCGCCGGCAGCTCCGGCACCCGGAGAAGACAACCCCGCCGGGGCTGGGGGAGCGGCGGTGGCCGGGGCTGCAGGAGGGGCTCGGCGGTTCCTCTGCGGTGTGGTGGAAGGATTTTATGGAAGACCTTGGGTTATGGAACAGAGAAAAGAACTCTTTAGAAGGCTCCAGAAATGGGAATTAAATACATACTTGTATGCCCCAAAAGATGACTACAAACATAGGATGTTTTGGCGAGAGATGTATTCAGTGGAGGAAGCTGAGCAACTTATGACTCTCATCTCTGCTGCACGAGAATATGAGATAGAGTTCATCTATGCGATCTCACCTGGATTGGATATCACTTTTTCTAACCCCAAGGAAGTATCCACATTGAAACGTAAATTGGACCAGGTTTCTCAGTTTGGGTGCAGATCATTTGCTTTGCTTTTTGATGATATAGACCATAATATGTGTGCAGCAGACAAAGAGGTATTCAGTTCTTTTGCTCATGCCCAAGTCTCCATCACAAATGAAATCTATCAGTACCTAGGAGAGCCAGAAACTTTCCTCTTCTGTCCCACAGAATACTGTGGCACTTTCTGTTATCCAAATGTGTCTCAGTCTCCATATTTAAGGACTGTGGGTGAAAAGCTTCTACCTGGAATTGAAGTGCTTTGGACAGGTCCCAAAGTTGTTTCTAAAGAAATTCCAGTAGAGTCCATCGAAGAGGTTTCTAAGATTATTAAGAGAGCTCCAGTAATCTGGGATAACATTCATGCTAATGATTATGATCAGAAGAGACTGTTTCTGGGCCCGTACAAAGGAAGATCCACAGAACTCATCCCACGGTTAAAAGGAGTCCTCACTAATCCAAATTGTGAATTTGAAGCCAACTACGTTGCTATCCACACCCTTGCCACCTGGTACAAATCAAACATGAATGGAGTGAGAAAAGATGTAGTGATGACTGACAGTGAAGATAGTACTGTGTCCATCCAGATAAAATTAGAAAATGAAGGCAGTGATGAAGATATTGAAACTGATGTACTCTATAGTCCACAGATGGCTCTAAAGCTAGCATTAACAGAATGGTTGCAAGAGTTTGGTGTGCCTCATCAATACAGCAGTAGGCAAGTTGCACACAGTGGAGCTAAAGCAAGTGTAGTTGATGGGACTCCTTTAGTTGCAGCACCCTCTTTAAATGCCACAACCGTAGTAACAACAGTTTATCAGGAGCCCATTATGAGCCAGGGAGCAGCCTTGAGTGGTGAGCCTACTACTCTGACCAAGGAAGAAGAAAAGAAACAGCCTGATGAAGAACCCATGGACATGGTGGTGGAAAAACAAGAAGAAACGGACCACAAGAATGACAATCAAATACTGAGTGAAATTGTTGAAGCGAAAATGGCAGAGGAATTGAAACCAATGGACACTGATAAAGAGAGCATAGCTGAATCAAAATCCCCAGAGATGTCCATGCAAGAAGATTGTATTAGTGACATTGCCCCCATGCAAACTGATGAACAGACAAACAAGGAGCAGTTTGTGCCAGGTCCAAATGAAAAGCCTTTGTACACTGCGGAACCAGTGACCCTGGAGGATTTGCAGTTACTTGCTGATCTATTCTACCTTCCTTACGAGCATGGACCCAAAGGAGCACAGATGTTACGGGAATTTCAATGGCTTCGAGCAAATAGTAGTGTTGTCAGTGTCAATTGCAAAGGAAAAGACTCTGAAAAAATTGAAGAATGGCGGTCACGAGCAGCCAAGTTTGAAGAGATGTGTGGACTAGTGATGGGAATGTTCACTCGGCTCTCCAATTGTGCCAACAGGACAATTCTTTATGACATGTACTCCTATGTTTGGGATATCAAGAGTATAATGTCTATGGTGAAGTCTTTTGTACAGTGGTTAGGGTGTCGTAGTCATTCTTCAGCACAATTCTTAATTGGAGACCAAGAACCCTGGGCCTTTAGAGGTGGTCTAGCAGGAGAGTTCCAGCGTTTGCTGCCAATTGATGGGGCAAATGATCTCTTTTTTCAGCCACCTCCACTGACTCCTACCTCCAAAGTTTATACTATCAGACCTTATTTTCCTAAGGATGAGGCATCCGTGTACAAGATTTGCAGAGAAATGTATGACGATGGAGTGGGTTTACCCTTTCAAAGTCAGCCTGATCTTATTGGAGACAAGTTAGTAGGAGGGCTGCTTTCCCTCAGCCTGGATTACTGCTTTGTCCTAGAAGATGAAGATGGCATATGTGGTTATGCCTTGGGCACTGTAGATGTGACCCCCTTTATTAAAAAATGTAAAATTTCCTGGATCCCCTTCATGCAGGAGAAGTATACCAAGCCAAATGGTGACAAGGAACTCTCTGAGGCTGAGAAAATAATGTTGAGTTTCCATGAAGAACAGGAAGTACTGCCAGAAACTTTCCTTGCTAATTTCCCTTCTCTGATAAAGATGGACATTCACAAAAAAGTAACTGACCCAAGTGTGGCCAAAAGCATGATGGCTTGCCTCCTGTCTTCACTGAAGGCTAATGGCTCCCGGGGAGCTTTCTGTGAAGTGAGACCAGATGATAAAAGAATTCTGGAATTTTACAGCAAGTTAGGATGTTTTGAAATTGCAAAAATGGAAGGATTTCCAAAGGATGTGGTTATACTTGGTCGGAGCCTGTGA
ORF Protein Sequence MVQKESQATLEERESELSSNPAASAGASLEPPAAPAPGEDNPAGAGGAAVAGAAGGARRFLCGVVEGFYGRPWVMEQRKELFRRLQKWELNTYLYAPKDDYKHRMFWREMYSVEEAEQLMTLISAAREYEIEFIYAISPGLDITFSNPKEVSTLKRKLDQVSQFGCRSFALLFDDIDHNMCAADKEVFSSFAHAQVSITNEIYQYLGEPETFLFCPTEYCGTFCYPNVSQSPYLRTVGEKLLPGIEVLWTGPKVVSKEIPVESIEEVSKIIKRAPVIWDNIHANDYDQKRLFLGPYKGRSTELIPRLKGVLTNPNCEFEANYVAIHTLATWYKSNMNGVRKDVVMTDSEDSTVSIQIKLENEGSDEDIETDVLYSPQMALKLALTEWLQEFGVPHQYSSRQVAHSGAKASVVDGTPLVAAPSLNATTVVTTVYQEPIMSQGAALSGEPTTLTKEEEKKQPDEEPMDMVVEKQEETDHKNDNQILSEIVEAKMAEELKPMDTDKESIAESKSPEMSMQEDCISDIAPMQTDEQTNKEQFVPGPNEKPLYTAEPVTLEDLQLLADLFYLPYEHGPKGAQMLREFQWLRANSSVVSVNCKGKDSEKIEEWRSRAAKFEEMCGLVMGMFTRLSNCANRTILYDMYSYVWDIKSIMSMVKSFVQWLGCRSHSSAQFLIGDQEPWAFRGGLAGEFQRLLPIDGANDLFFQPPPLTPTSKVYTIRPYFPKDEASVYKICREMYDDGVGLPFQSQPDLIGDKLVGGLLSLSLDYCFVLEDEDGICGYALGTVDVTPFIKKCKISWIPFMQEKYTKPNGDKELSEAEKIMLSFHEEQEVLPETFLANFPSLIKMDIHKKVTDPSVAKSMMACLLSSLKANGSRGAFCEVRPDDKRILEFYSKLGCFEIAKMEGFPKDVVILGRSL

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-T19567-Ab Anti-OGA monoclonal antibody
    Target Antigen GM-Tg-g-T19567-Ag OGA protein
    ORF Viral Vector pGMAD000486 Human OGA Adenovirus plasmid
    ORF Viral Vector pGMAD001646 Human OGA Adenovirus plasmid
    ORF Viral Vector pGMPC001034 Human OGA Mammalian (Non-Viral Vector) plasmid
    ORF Viral Vector vGMAD000486 Human OGA Adenovirus particle
    ORF Viral Vector vGMAD001646 Human OGA Adenovirus particle


    Target information

    Target ID GM-T19567
    Target Name OGA
    Gene ID 10724, 76055, 712370, 154968, 101098493, 477802, 538561, 100060245
    Gene Symbol and Synonyms Hy5,MEA5,MGEA5,NCOAT,OGA
    Uniprot Accession O60502
    Uniprot Entry Name OGA_HUMAN
    Protein Sub-location Introcelluar Protein
    Category Therapeutics Target
    Disease Acute kidney failure, Chronic tubulo-interstitial nephritis, Diabetic Nephropathy, Intraoperative Renal Injury, Nephropathy induced by heavy metals, Nephropathy induced by other drugs, medicaments and biological substances, Proteinuria, Sickle Cell Nephropathy, Type 1 diabetes mellitus with diabetic nephropathy, Type 2 diabetes mellitus
    Gene Ensembl ENSG00000198408
    Target Classification Not Available

    The dynamic modification of cytoplasmic and nuclear proteins by O-linked N-acetylglucosamine (O-GlcNAc) addition and removal on serine and threonine residues is catalyzed by OGT (MIM 300255), which adds O-GlcNAc, and MGEA5, a glycosidase that removes O-GlcNAc modifications (Gao et al., 2001 [PubMed 11148210]).[supplied by OMIM, Mar 2008]



    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.